Health Care [ 5/12 ] | Biotechnology [ 29/74 ]
NASDAQ | Common Stock
Moderna, Inc., a biotechnology company, provides messenger RNA medicines in the United States, Europe, and internationally.
The company's respiratory vaccines include spikevax, mRESVIA, COVID, RSV, seasonal influenza, combination, and pandemic influenza vaccine; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; enteric viruses include norovirus; public health vaccines consist of Zika, Nipah, and Mpox vaccines; and bacterial diseases vaccines, such as lyme vaccines.
It also provides oncology therapeutics, such as individualized neoantigen and checkpoint adaptive immune modulation therapy; and rare disease products, including propionic and methylmalonic acidemia, glycogen storage disease type 1a, ornithine transcarbamylase deficiency, phenylketonuria, crigler-najjar syndrome type 1, and cystic fibrosis.
It has strategic alliances and collaborations with AstraZeneca; Merck & Co., Inc; Vertex Pharmaceuticals Incorporated; Vertex Pharmaceuticals (Europe) Limited; Generation Bio Co.; immaticsN. V.; Life Edit Therapeutics; Carisma Therapeutics, Inc.; CytomX Therapeutics; Defense Advanced Research Projects Agency; Biomedical Advanced Research and Development Authority; Institute for Life Changing Medicines; The Bill & Melinda Gates Foundation; and OpenAI.
The company was formerly known as Moderna Therapeutics, Inc. and changed its name to Moderna, Inc. in August 2018.
Moderna, Inc. was founded in 2010 and is headquartered in Cambridge, Massachusetts.
| Reported date | EPSChange YoY | EstimateSurprise |
|---|---|---|
| Feb 20, 25 | -2.91 Decreased by -629.09% | -2.76 Decreased by -5.44% |
| Nov 7, 24 | 0.03 Increased by +100.31% | -1.90 Increased by +101.58% |
| Aug 1, 24 | -3.33 Increased by +8.01% | -3.38 Increased by +1.48% |
| May 2, 24 | -3.07 Decreased by -1.72 K% | -3.58 Increased by +14.25% |
| Feb 22, 24 | 0.55 Decreased by -84.76% | -0.97 Increased by +156.70% |
| Nov 2, 23 | -9.53 Decreased by -476.68% | -1.93 Decreased by -393.78% |
| Aug 3, 23 | -3.62 Decreased by -169.08% | -4.04 Increased by +10.40% |
| May 4, 23 | 0.19 Decreased by -97.79% | -1.77 Increased by +110.73% |
| Fiscal ending date | RevenueChange YoY | IncomeChange YoY | ProfitChange YoY |
|---|---|---|---|
| Dec 31, 24 | 966.00 M Decreased by -65.66% | -1.12 B Decreased by -616.13% | Decreased by -115.94% Decreased by -1.60 K% |
| Sep 30, 24 | 1.85 B Increased by +1.31% | 13.00 M Increased by +100.36% | Increased by +0.70% Increased by +100.35% |
| Jun 30, 24 | 241.00 M Decreased by -29.94% | -1.28 B Increased by +7.32% | Decreased by -530.71% Decreased by -32.29% |
| Mar 31, 24 | 167.00 M Decreased by -91.03% | -1.18 B Decreased by -1.59 K% | Decreased by -703.59% Decreased by -16.68 K% |
| Dec 31, 23 | 2.81 B Decreased by -44.67% | 217.00 M Decreased by -85.19% | Increased by +7.71% Decreased by -73.23% |
| Sep 30, 23 | 1.83 B Decreased by -43.14% | -3.63 B Decreased by -448.03% | Decreased by -198.25% Decreased by -712.05% |
| Jun 30, 23 | 344.00 M Decreased by -92.47% | -1.38 B Decreased by -162.81% | Decreased by -401.16% Decreased by -933.73% |
| Mar 31, 23 | 1.86 B Decreased by -68.65% | 79.00 M Decreased by -97.84% | Increased by +4.24% Decreased by -93.11% |